Viewing Study NCT04014205


Ignite Creation Date: 2025-12-25 @ 3:33 AM
Ignite Modification Date: 2026-02-17 @ 5:50 PM
Study NCT ID: NCT04014205
Status: UNKNOWN
Last Update Posted: 2023-04-18
First Post: 2019-06-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Part 1:r/r B-cell Malignancies View
None Part 2:B-cell Malignancies View
Keywords: